Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | PPARA | Q07869 | 6/20 | 0.46 |
| ▸ | PPARG | P37231 | 4/20 | 0.46 |
| ▸ | EPOR | P19235 | 1/20 | 0.43 |
| ▸ | PTGIR | P43119 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16124584 | 0.94 | ACHE (0.49) | ACHEPPARAPPARGEPORMAPK1 | |
| SCHEMBL16124583 | 0.85 | THRB (0.47) | ERAP2LNPEPLTA4HERAP1 | |
| SCHEMBL16124582 | 0.85 | PPARA (0.49) | ACHEPPARAPPARGCYP2D6 | |
| SCHEMBL14135115 | 0.84 | ACHE (0.44) | ACHEEPORMAPK1L3MBTL1LNPEP | |
| SCHEMBL13416281 | 0.83 | ACHE (0.44) | ACHEEPORMAPK1L3MBTL1ERAP2 | |
| SCHEMBL13396512 | 0.82 | ACHE (0.40) | ACHEEPORMAPK1L3MBTL1LTA4H | |
| SCHEMBL13396417 | 0.81 | ACHE (0.40) | ACHEEPORMAPK1L3MBTL1ERAP2 | |
| Hydrochloric Acid SCHEMBL5064601 | 0.80 | LMNA (0.48) | EPORMAPK1LTA4H | |
| SCHEMBL16124599 | 0.79 | PPARA (0.48) | ACHEPPARAPPARGPTGIRCYP2D6 | |
| SCHEMBL16124585 | 0.79 | THRB (0.48) | PPARAPPARGEPORERAP2LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | ACHE 394/4885PPARA 2870/4885PPARG 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.